BioSpace News Archive

AxoSim, Inc. announced completion of its acquisition of the microBrain™ associated assets of Vyant Bio’s StemoniX subsidiary.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that it plans to release financial results for the third quarter ended September 30, 2023 on November 7, 2023.

AstraZeneca’s Supplemental Biologics License Application for the approval of a self- or caregiver-administered option for FLUMIST® QUADRIVALENT, a needle-free nasal spray, has been accepted for review by the US Food and Drug Administration.

KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, announced clearance of an Investigational New Drug application by the United States Food and Drug Administration to initiate a Phase 1 clinical study of ASP1012 in participants with locally advanced or metastatic solid tumors.

SciSparc Ltd. announced today that it received a notice of acceptance for its patent application for the Combinations of Cannabinoids and N-Acylethanolamines (the “Patent”).

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of Prime Editors to efficiently and precisely correct the predominant mutations that cause rhodopsin associated autosomal dominant retinitis pigmentosa (RHO adRP).

Mind Medicine announced today that it has completed enrollment of Study MMED007, the Company’s Phase 2a study evaluating repeated low-dose administration of MM-120 (lysergide D-tartrate) for the treatment of adults with ADHD.

Evofem Biosciences, Inc. today announced preliminary results for the third quarter of 2023, including sequential growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate) and the positive impact of ongoing cost containment initiatives.

ITM Isotope Technologies Munich SE reported on its participation at the 3rdInternational Centers for Precision Oncology Forum for Theranostics in Precision Oncology which took place in Garching near Munich, Germany, from October 12-13, 2023.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.